Back-to-School at USP
Brian McNally, PhD, director of global biologics marketing & strategic collaborations at USP provides his insight on building the workforce behind the next generation of medicines. Don't miss this August issue Point of View. The post Back-to-School at USP appeared first on GEN - Genetic Engineering and Biotechnology News .
The pharmaceutical and biotechnology industries are undergoing a significant surge in investment globally. Notable investments include AstraZeneca's $4.5 billion expansion near Charlottesville, Virginia, Merck's $3 billion manufacturing center in Elkton, and Eli Lilly's $5 billion facility in Goochland County, all of which represent thousands of new jobs and over $16 billion in capital investment.
However, these investments are contingent upon a well-trained workforce capable of developing, manufacturing, testing, and regulating high-quality medicines. This workforce readiness has become a key focus within the industry. At the BIO International Convention in June, discussions centered on future-ready solutions to address talent challenges in global biomanufacturing.
Industry leaders emphasized the necessity of parallel investments in education, training, and talent development to sustain growth in the life sciences sector.
To support this workforce readiness, major pharmaceutical companies like AstraZeneca, Eli Lilly, and Merck have committed up to $120 million towards the Virginia Center for Advanced Pharmaceutical Manufacturing. Additionally, Eli Lilly has partnered with Lehigh Carbon Community College in Pennsylvania to establish a pharmaceutical workforce development hub.
These initiatives signify a broader trend beyond the United States, with Australia, South Korea, and other countries investing in similar workforce development programs to support their growing pharmaceutical ecosystems.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
